Amyris, Inc.
Index- P/E- EPS (ttm)-1.07 Insider Own0.70% Shs Outstand322.29M Perf Week-3.26%
Market Cap575.85M Forward P/E- EPS next Y-0.66 Insider Trans-64.33% Shs Float229.96M Perf Month-35.27%
Income-341.10M PEG- EPS next Q-0.28 Inst Own39.40% Short Float / Ratio19.71% / 7.01 Perf Quarter-34.80%
Sales258.80M P/S2.23 EPS this Y50.80% Inst Trans-14.37% Short Interest45.33M Perf Half Y-25.21%
Book/sh-1.33 P/B- EPS next Y54.20% ROA-40.20% Target Price7.89 Perf Year-70.13%
Cash/sh0.06 P/C31.13 EPS next 5Y30.00% ROE222.60% 52W Range1.44 - 6.79 Perf YTD-67.10%
Dividend- P/FCF- EPS past 5Y31.50% ROI-30.40% 52W High-73.78% Beta1.15
Dividend %- Quick Ratio0.50 Sales past 5Y38.50% Gross Margin10.70% 52W Low23.60% ATR0.25
Employees980 Current Ratio0.90 Sales Q/Q48.40% Oper. Margin- RSI (14)40.06 Volatility10.93% 12.48%
OptionableYes Debt/Eq- EPS Q/Q-357.40% Profit Margin- Rel Volume0.79 Prev Close1.80
ShortableYes LT Debt/Eq- EarningsNov 08 AMC Payout- Avg Volume6.46M Price1.78
Recom2.50 SMA20-16.07% SMA50-29.21% SMA200-40.61% Volume5,108,882 Change-1.11%
Nov-10-22Downgrade JP Morgan Overweight → Neutral
Nov-09-22Downgrade Oppenheimer Outperform → Perform
Aug-10-22Downgrade ROTH Capital Buy → Neutral $4 → $2
Jun-24-22Initiated JP Morgan Neutral
May-25-22Initiated Piper Sandler Neutral $2.50
Mar-02-22Resumed Cowen Outperform
Oct-15-21Resumed Cowen Outperform $19
Jun-01-21Initiated HSBC Securities Buy $20
Mar-03-21Reiterated H.C. Wainwright Buy $11 → $35
Feb-26-21Initiated ROTH Capital Buy $20
Show Previous Ratings
Nov-30-22 08:00AM
Nov-28-22 08:56AM
Nov-09-22 05:58PM
Nov-08-22 06:05PM
06:31PM Loading…
Nov-07-22 06:31PM
Nov-04-22 05:58PM
Nov-01-22 08:00AM
Oct-25-22 08:00AM
Oct-24-22 08:00AM
Oct-14-22 06:58PM
Oct-11-22 08:43AM
Sep-18-22 08:59AM
Sep-07-22 08:00AM
Sep-01-22 12:43PM
04:06PM Loading…
Aug-31-22 04:06PM
Aug-29-22 05:29AM
Aug-14-22 06:49PM
Aug-12-22 06:29AM
Aug-09-22 10:01PM
Aug-03-22 08:00AM
Aug-02-22 10:26AM
Jul-28-22 08:00AM
Jul-03-22 09:43AM
Jun-27-22 08:00AM
Jun-24-22 06:45AM
Jun-23-22 08:00AM
Jun-07-22 08:00AM
05:31AM Loading…
May-31-22 05:31AM
May-23-22 05:36PM
May-22-22 06:11AM
May-12-22 07:48AM
May-10-22 08:30PM
May-03-22 08:00AM
May-02-22 07:47AM
Apr-28-22 06:15PM
Apr-14-22 08:00AM
Apr-11-22 08:00AM
Apr-08-22 06:15PM
Apr-06-22 11:45AM
Mar-29-22 08:00AM
Mar-24-22 06:07AM
Mar-17-22 08:00AM
Mar-15-22 06:15PM
Mar-11-22 08:00AM
Mar-04-22 07:05AM
Mar-01-22 08:00AM
Feb-28-22 08:00AM
Feb-27-22 10:52AM
Feb-22-22 08:00AM
Feb-14-22 06:15PM
Feb-09-22 08:00AM
Feb-08-22 06:15PM
Feb-03-22 05:38PM
Feb-02-22 09:38AM
Feb-01-22 06:15PM
Jan-27-22 08:00AM
Jan-26-22 06:15PM
Jan-24-22 08:00AM
Jan-18-22 09:38AM
Jan-14-22 06:15PM
Jan-13-22 10:56AM
Jan-07-22 06:15PM
Jan-05-22 08:00AM
Jan-03-22 12:50PM
Dec-23-21 07:00AM
Dec-20-21 08:35AM
Dec-18-21 05:43AM
Dec-15-21 01:38AM
Dec-12-21 07:00AM
Dec-10-21 05:15PM
Dec-08-21 12:57PM
Nov-30-21 08:00AM
Nov-23-21 04:05PM
Nov-18-21 09:12AM
Nov-15-21 05:31PM
Nov-11-21 07:15PM
Nov-10-21 08:00AM
Nov-09-21 02:50PM
Nov-08-21 06:05PM
Oct-28-21 03:06PM
Oct-27-21 06:17AM
Oct-25-21 10:08AM
Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kung FrankDirectorSep 21Sale3.50200,000700,0000Sep 22 08:19 PM
Kung FrankDirectorSep 20Sale3.60400,0001,440,00036,488Sep 22 08:19 PM
Kung FrankDirectorSep 19Sale3.801,080,6764,106,569109,460Sep 19 09:00 PM
Kung FrankDirectorSep 16Sale3.60833,1002,999,160306,608Sep 19 09:00 PM
Kung FrankDirectorSep 15Sale4.201,385,0005,817,000458,591Sep 19 09:00 PM
ALVAREZ EDUARDOCHIEF OPERATING OFFICERSep 02Sale2.8722,42164,348351,914Sep 07 08:08 PM
KELSEY NICOLECHIEF LEGAL OFFICER- SECRETARYSep 02Sale2.875,01914,40558,314Sep 07 08:08 PM
Kieftenbeld HermanusCHIEF FINANCIAL OFFICERSep 02Sale2.8725,88874,299240,767Sep 07 08:08 PM
Melo JohnPresident and CEOAug 15Buy4.0317,15569,135509,856Aug 17 02:17 PM
Melo JohnPresident and CEOJul 06Sale2.1255,576117,918492,701Jul 08 04:38 PM
KELSEY NICOLECHIEF LEGAL OFFICER- SECRETARYJun 30Sale1.8094,033169,41963,333Jul 01 04:45 PM
Hughes AnthonyCHIEF ACCOUNTING OFFICERJun 02Sale2.346,30514,754106,612Jun 03 06:09 PM
Kieftenbeld HermanusCHIEF FINANCIAL OFFICERJun 02Sale2.3434,90581,681266,655Jun 03 06:09 PM
KELSEY NICOLECHIEF LEGAL OFFICER- SECRETARYJun 02Sale2.348,40619,671157,366Jun 03 06:09 PM
MCCANN JAMES FDirectorDec 06Buy5.7117,40099,35429,831Dec 08 07:51 PM